H5N1, Influenza, vaccine, parent protocol
Showing 1 - 25 of >10,000
Influenza, Human Trial (FLU Q-PAN H5N8 Formulation 1, AS03B, AS03A)
Not yet recruiting
- Influenza, Human
- FLU Q-PAN H5N8 Formulation 1
- +3 more
- (no location specified)
Jul 27, 2023
Influenza Trial in Baltimore (H5N1 pISV)
Completed
- Influenza
- H5N1 pISV
-
Baltimore, MarylandCenter for Immunization Research, Johns Hopkins Bloomberg School
Feb 15, 2022
Influenza, Human, Infections, Respiratory Tract Infections Trial in United States (aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on
Not yet recruiting
- Influenza, Human
- +4 more
- aH5N8c on Day 1
- +4 more
-
Cullman, Alabama
- +8 more
May 15, 2023
Influenza, Human, Influenza in Birds, Respiratory Tract Infections Trial in United States (aH5N6c on Day 1, aH5N6c on Day 22,
Recruiting
- Influenza, Human
- +7 more
- aH5N6c on Day 1
- +2 more
-
Huntsville, Alabama
- +17 more
Jul 26, 2022
Influenza, Human Trial in Estonia, Philippines (H5N1 antigen combined with MF59 adjuvant)
Completed
- Influenza, Human
- H5N1 antigen combined with MF59 adjuvant
-
Tallinn, Harjumaa, Estonia
- +6 more
Jul 21, 2022
Influenza Trial in South Jordan (mRNA-1018 for H5N8, mRNA-1018 for H7N9, mRNA-1018 for H5 Only)
Recruiting
- Influenza
- mRNA-1018 for H5N8
- +4 more
-
South Jordan, UtahJ. Lewis Research, Inc/Jordan River Family Medicine
Jul 25, 2023
Influenza Vaccine Trial in United States (Cam2020 M2SR H3N2 influenza vaccine, Fluzone HD IIV, IN Placebo)
Completed
- Influenza Vaccine
- Cam2020 M2SR H3N2 influenza vaccine
- +3 more
-
Port Orange, Florida
- +5 more
Nov 11, 2022
Influenza, Pandemic Trial in Baltimore (BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette -
Recruiting
- Influenza, Pandemic
- BW-1014: 25 µg rH5 in 20% NE - pipette - IN
- +5 more
-
Baltimore, MarylandCenter for Vaccine Development and Global Health, University of
Jul 8, 2022
Influenza, Human, Infections, Respiratory Tract Infections Trial in Philippines, United States (Low dose A/H2N3c + standard dose
Not yet recruiting
- Influenza, Human
- +4 more
- Low dose A/H2N3c + standard dose MF59
- +5 more
-
Rockville, Maryland
- +7 more
May 26, 2023
Influenza Vaccine Trial in Anaheim, DeLand, Lenexa (Sing2016 M2SR H3N2 influenza vaccine, Placebo)
Active, not recruiting
- Influenza Vaccine
- Sing2016 M2SR H3N2 influenza vaccine
- Placebo
-
Anaheim, California
- +2 more
May 13, 2022
Avian Influenza, H1N1 Influenza, Influenza Trial in Nashville (AS03, Influenza Virus Vaccine, Monovalent A/H3N2v
Completed
- Avian Influenza
- +2 more
- AS03
- +2 more
-
Nashville, TennesseeVanderbilt University Medical Center - Vanderbilt Institute for
Jan 25, 2022
Pandemic Influenza Trial in United States (A/H5N1, LT Adjuvant Patch)
Completed
- Pandemic Influenza
- A/H5N1
- LT Adjuvant Patch
-
Anaheim, California
- +5 more
Dec 9, 2021
Influenza A Trial in United States (LD Sing2016 M2SR H3N2 influenza vaccine, MD Sing2016 M2SR H3N2 influenza vaccine, HD
Completed
- Influenza A
- LD Sing2016 M2SR H3N2 influenza vaccine
- +4 more
-
Hollywood, Florida
- +3 more
Dec 10, 2021
Influenza Trial in Canada, United States (High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 µg (split-virion, inactivated),
Completed
- Influenza
- High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)
- +4 more
-
San Diego, California
- +15 more
Mar 24, 2022
Influenza, Influenza Vaccines Trial in Canada, Thailand, United States (Influenza A (H5N1) Virus monovalent vaccine, Saline )
Completed
- Influenza
- Influenza Vaccines
- Influenza A (H5N1) Virus monovalent vaccine
- Saline placebo
-
Paramount, California
- +16 more
Oct 19, 2021
H3N2 Influenza Trial in United States (Placebo, Sing2016 M2SR H3N2)
Recruiting
- H3N2 Influenza
- Placebo
- Sing2016 M2SR H3N2
-
Iowa City, Iowa
- +3 more
Mar 10, 2022
Influenza Trial in Canada (aTIV Primer, QIV Primer, aTIV Booster)
Completed
- Influenza
- aTIV Primer
- +3 more
-
Vancouver, British Columbia, Canada
- +3 more
Jan 28, 2022
Influenza Trial in Beijing (split-virion, adjuvanted H1N1 vaccine of 7.5 µg per dose, split-virion, adjuvanted H1N1 vaccine of
Completed
- Influenza
- split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose
- +6 more
-
Beijing, ChinaBeijing Centers for Diseases Control and Prevention
Jul 26, 2021
Respiratory Syncytial Virus Infections Trial in Worldwide (RSV MAT Lot 1 vaccine (GSK3888550A), RSV MAT Lot 2 vaccine
Completed
- Respiratory Syncytial Virus Infections
- RSV MAT Lot 1 vaccine (GSK3888550A)
- +4 more
-
West Palm Beach, Florida
- +35 more
Jul 14, 2022
Pandemic Influenza Disease Trial in Tampere, München (Placebo (PL), Trivalent influenza virus vaccine (TIV), Adjuvanted
Completed
- Pandemic Influenza Disease
- Placebo (PL)
- +3 more
-
Tampere, Finland
- +1 more
Apr 22, 2021
Respiratory Syncytial Viruses Trial in Canada, United Kingdom, United States (RSVPreF3 OA investigational vaccine, HZ/su
Not yet recruiting
- Respiratory Syncytial Viruses
- RSVPreF3 OA investigational vaccine
- HZ/su vaccine
-
Daphne, Alabama
- +23 more
Jul 21, 2023
Influenza, Human Trial in United States (FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation
Active, not recruiting
- Influenza, Human
- FLU-Q-PAN H7N9 Formulation 1
- +5 more
-
Stockbridge, Georgia
- +6 more
Apr 18, 2022
Pneumococcal Vaccines Trial in Canada (IVT PCV-25 Formulation A, IVT PCV-25 Formulation B, IVT PCV-25 Formulation C)
Not yet recruiting
- Pneumococcal Vaccines
- IVT PCV-25 Formulation A
- +3 more
-
Vancouver, British Columbia, Canada
- +3 more
Oct 10, 2023
Influenza Trial in Canada, Dominican Republic, Honduras (Quadrivalent influenza GSK2282512A vaccine, Fluarix)
Completed
- Influenza
- Quadrivalent influenza GSK2282512A vaccine
- Fluarix
-
Halifax, Nova Scotia, Canada
- +7 more
Oct 19, 2021
Low Back Disorder, Shoulder Disease, Musculoskeletal Injury Trial (Remote functional testing protocol)
Recruiting
- Low Back Disorder
- +2 more
- Remote functional testing protocol
-
London, Ontario, Canada
- +4 more
Nov 22, 2022